Terms: = Skin cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Treatment
31 results:
1. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
Bai X; Attrill GH; Gide TN; Ferguson PM; Nahar KJ; Shang P; Vergara IA; Palendira U; da Silva IP; Carlino MS; Menzies AM; Long GV; Scolyer RA; Wilmott JS; Quek C
Nat Commun; 2024 Apr; 15(1):3014. PubMed ID: 38589406
[TBL] [Abstract] [Full Text] [Related]
2. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract] [Full Text] [Related]
3. [Successful Postoperative Recurrence treatment of Malignant Melanoma of the Esophagus by Anti-PD-1 and Anti-CTLA-4 Combined Therapy-A Case Report].
Minagawa Y; Tanaka Y; Funatsuya T; Takahashi M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1160-1162. PubMed ID: 36281619
[TBL] [Abstract] [Full Text] [Related]
4. Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
Yi G; Huang Z; Huang Z; Wang Y; Deng W; Zheng S; Li T
Front Immunol; 2022; 13():914265. PubMed ID: 35874753
[TBL] [Abstract] [Full Text] [Related]
5. sil-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
Barak V; Kalickman I; Pe'er J
Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
[TBL] [Abstract] [Full Text] [Related]
6. Uncovering Barriers to Screening for Distress in Patients With cancer via Machine Learning.
Günther MP; Kirchebner J; Schulze JB; Götz A; von Känel R; Euler S
J Acad Consult Liaison Psychiatry; 2022; 63(2):163-169. PubMed ID: 34438098
[TBL] [Abstract] [Full Text] [Related]
7. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
Takai R; Funakoshi Y; Suto H; Nagatani Y; Imamura Y; Toyoda M; Yakushijin K; Kiyota N; Harada KI; Yamashita K; Kakeji Y; Minami H
Anticancer Res; 2021 Feb; 41(2):1021-1026. PubMed ID: 33517310
[TBL] [Abstract] [Full Text] [Related]
8. Human T-lymphotropic virus type I proviral loads in patients with adult T-cell leukemia-lymphoma: Comparison between cutaneous type and other subtypes.
Yonekura K; Utsunomiya A; Seto M; Takatsuka Y; Takeuchi S; Tokunaga M; Kubota A; Takeda K; Kanzaki T; Uchida Y; Kawai K; Kanekura T
J Dermatol; 2015 Dec; 42(12):1143-8. PubMed ID: 26134467
[TBL] [Abstract] [Full Text] [Related]
9. Serum TNF-α, B2M and sil-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract] [Full Text] [Related]
10. Pretreatment levels of sTNF-R1 and sil-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract] [Full Text] [Related]
11. Serological immunomarkers in cutaneous T cell lymphoma.
Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
[TBL] [Abstract] [Full Text] [Related]
12. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG
Br J Cancer; 2004 Mar; 90(5):955-61. PubMed ID: 14997189
[TBL] [Abstract] [Full Text] [Related]
13. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Groenewegen G; Bloem A; De Gast GC
Cancer Immunol Immunother; 2002 Dec; 51(11-12):630-6. PubMed ID: 12439608
[TBL] [Abstract] [Full Text] [Related]
14. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
[TBL] [Abstract] [Full Text] [Related]
15. [Gene modified tumor vaccines in therapy of malignant melanoma].
Wysocki PJ; Karczewska A; Mackiewicz A
Otolaryngol Pol; 2002; 56(2):147-53. PubMed ID: 12094637
[TBL] [Abstract] [Full Text] [Related]
16. treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract] [Full Text] [Related]
17. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
[TBL] [Abstract] [Full Text] [Related]
18. T-cell evaluation in patients with colon cancer: dinitrochlorobenzene skin testing versus plasma levels of sil-2r and sCD8.
Bleeker WA; de Ley L; Oeseburg HB; Martens A; Mulder NH; Hermans J; Plukker JT
Ann Surg Oncol; 1998; 5(3):209-12. PubMed ID: 9607619
[TBL] [Abstract] [Full Text] [Related]
19. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract] [Full Text] [Related]
20. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract] [Full Text] [Related]
[Next]
